Eli Lilly and Company

Thank you for holding. We look forward to talking with you soon. Please hold the line, and we'll be right back with you.

Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. At this time, all participants are on a listen-only mode. Later, we will be conducting a question and answer session and instructions will be given at that time. Should you request assistance during the call, please press star, then zero, and an operator will assist you offline. I would now like to turn the conference over to your host, Mike Zappar, Senior Vice President of Investor Relations. Mike, please go ahead.

Good morning. Thank you for joining us for Ilya Lillian Company's Q4 2024 Earnings Call. I'm Mike Savar, Senior Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lillian's Chair and CEO, Dr. Dan Skowronski, Chief Scientific Officer and President of Lillian Immunology, Lucas Montarse, Chief Financial Officer, Anne White, President of Lillian Neuroscience, Ilya Yufa, President of Lillian International, Jake Van Narden, President of Lillian Oncology, and Patrick Johnson, President of Lilly Cardio Metabolic Health and Lilly USA. We're also joined by Mark Heumann, Wes Tall, and Wai Wong of the Investor Relations Team. During the call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to several factors, including those listed on slide four. Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent filings with the SEC. The information we provide about our products and pipeline is for the benefit of the investment community. It is not intended to be promotional and is not sufficient for prescribing decisions. As we transition to our prepared remarks, please note that our commentary will focus on our non-GAAP financial measures. Now, I'll turn the call over to Dave. Okay, thanks, Mike.